Abstract
Purpose
6-O-(2-[18F]Fluoroethyl)-6-O-desmethyl-diprenorphine ([18F]FE-DPN) is regarded as a non-selective opioid receptor radiotracer.
Procedure
Here, we report the first characterization of [18F]FE-DPN synthesized from the novel precursor, 6-O-(2-tosyloxyethoxy)-6-O-desmethyl-3-O-trityl-diprenorphine (TE-TDDPN), using a one-pot, two-step nucleophilic radiosynthesis to image opioid receptors in rats and mice using positron emission tomography.
Results
We also show that [18F]FE-DPN and [3H]DPN exhibit negligible brain uptake in mu opioid receptor (MOR) knockout mice.
Conclusions
Taken together with prior findings, our results suggest that [18F]FE-DPN and [3H]DPN preferentially bind to MOR in rodents in vivo.
Similar content being viewed by others
References
Wester HJ, Willoch F, Tolle TR et al (2000) 6-O-(2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine ([18F]DPN): synthesis, biologic evaluation, and comparison with [11C]DPN in humans. J Nucl Med 41:1279–1286
Mueller C, Klega A, Buchholz HG et al (2010) Basal opioid receptor binding is associated with differences in sensory perception in healthy human subjects: a [18F]diprenorphine PET study. Neuroimage 49:731–737
Thompson SJ, Pitcher MH, Stone LS et al (2018) Chronic neuropathic pain reduces opioid receptor availability with associated anhedonia in rat. Pain 159:1856–1866
Raynor K, Kong H, Chen Y et al (1994) Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 45:330–334
Chang KJ, Hazum E, Cuatrecasas P (1980) Possible role of distinct morphine and enkephalin receptors in mediating actins of benzomorphan drugs (putative kappa and sigma agonists). Proc Natl Acad Sci U S A 77:4469–4473
Chang KJ, Hazum E, Cuatrecasas P (1981) Novel opiate binding sites selective for benzomorphan drugs. Proc Natl Acad Sci U S A 78:4141–4145
Henriksen G, Willoch F, Talbot PS, Wester HJ (2006) Recent development and potential use of mu- and kappa-opioid receptor ligands in positron emission tomography studies. Drug Develop Res 67:890–904
Schoultz BW, Hjornevik T, Reed BJ et al (2014) Synthesis and evaluation of three structurally related (1)(8)F-labeled orvinols of different intrinsic activities: 6-O-[(1)(8)F]fluoroethyl-diprenorphine ([(1)(8)F]FDPN), 6-O-[(1)(8)F]fluoroethyl-buprenorphine ([(1)(8)F]FBPN), and 6-O-[(1)(8)F]fluoroethyl-phenethyl-orvinol ([(1)(8)F]FPEO). J Med Chem 57:5464–5469
Frost JJ, Dannals RF, Duelfer T et al (1984) In vivo studies of opiate receptors. Ann Neurol 15(Suppl):S85-92
Zeeberg BR (1999) Pharmacokinetic computer simulations of the relationship between in vivo and in vitro neuroreceptor subtype selectivity of radioligands. Nucl Med Biol 26:803–809
Frost JJ, Smith AC, Wagner HN Jr (1986) 3H-diprenorphine is selective for mu opiate receptors in vivo. Life Sci 38:1597–1606
Atweh SF, Kuhar MJ (1977) Autoradiographic localization of opiate receptors in rat brain III. The telencephalon Brain Res 134:393–405
Marton J, Cumming P, Bauer B, Henriksen G (2021) A new precursor for the radiosynthesis of 6-O-(2-[(18) F]fluoroethyl)-6-O-desmethyl-diprenorphine ([F-18]FE-DPN) by nucleophilic radiofluorination. Lett Org Chem 18:344–352
Bonaventura J, Lam S, Carlton M et al (2021) Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry 26:6704–6722
Ichise M, Ballinger JR, Golan H et al (1996) Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 37:513–520
Kitchen I, Slowe SJ, Matthes HW, Kieffer B (1997) Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. Brain Res 778:73–88
Cumming P, Marton J, Lilius TO, Olberg DE, Rominger A (2019) A survey of molecular imaging of opioid receptors. Molecules 24:4190.
Funding
This work was supported by the NIDA Intramural Research Program (ZIA000069, MM) and by Grants RYC-2019-027371-I (JB) funded by MCIN/AEI/1013039/501100011033 and by “ESF Investing in your future,” Plan Nacional Sobre Drogas 2021I070 (JB) funded by the Spanish Ministerio de Sanidad, and (EB024495, MGP) funded by NIBIB.
Author information
Authors and Affiliations
Contributions
Designed and performed experiments, analyzed data, and wrote the manuscript: MRL, MM. Designed experiments, analyzed data, and wrote the manuscript: JB. Designed and performed experiments: ENV, JLG, DH. Performed experiments: RCB. Contributed resources and reagents: MJ, GH, RFD, MGP, CAZ. All coauthors reviewed the manuscript and provided comments.
Corresponding author
Ethics declarations
Conflict of Interest
MM has received research funding from AstraZeneca, Redpin Therapeutics, and Attune Neurosciences. CAZ is listed as a coinventor on a patent for the use of ketamine in major depression and suicidal ideation. CAZ is listed as a coinventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. CAZ is listed as coinventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. CAZ has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors declare no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Levinstein, M.R., Ventriglia, E.N., Gomez, J.L. et al. 6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo. Mol Imaging Biol 25, 384–390 (2023). https://doi.org/10.1007/s11307-022-01767-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-022-01767-5